Advertisement

Topic - Horizon Therapeutics Plc

Related Stories

This photo shows signage outside the Amgen headquarters in Thousand Oaks, Calif on Nov. 9, 2014. Federal regulators are suing to block biotech drug developer Amgen’s more than $26 billion deal for Horizon Therapeutics. The Federal Trade Commission said Tuesday, May 16, 2023, that the deal, announced last December, would give Amgen unfair leverage to block competition for Horizon medications. (AP Photo/Mark J. Terrill, File)

Monopoly concerns push FTC to sue to block Amgen’s more than $26B deal for Horizon

Associated Press

This photo shows signage outside the Amgen headquarters in Thousand Oaks, Calif on Nov. 9, 2014. Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases, in a deal valued at approximately $26.4 billion. (AP Photo/Mark J. Terrill, File)

Amgen to buy Horizon Therapeutics in $26.4B deal

By Tom Murphy - Associated Press